drugset / Trial / NCT01489865
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
People are being asked to participate in this study who have metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and mFOLFOX-6 (modified 5-Fluorouracil and Oxaliplatin) for patients with metastatic pancreatic cancer. ABT-888 inhibits an enzyme called "PARP" which helps to fix damaged DNA. By inhibiting this enzyme, ABT-888 prevents cancer cells from repairing the damage caused by the mFOLFOX-6, and will hopefully increase the killing of cancer cells, thus decreasing the tumors in your body.
Timeline
- Start
- 2011-01-03
- Primary completion
- 2018-12-26
- Completion
- 2023-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Veliparib | Small molecule | 40 mg | Oral |
| Subject | Veliparib | Small molecule | 60 mg | Oral |
| Subject | Veliparib | Small molecule | 80 mg | Oral |
| Subject | Veliparib | Small molecule | 100 mg | Oral |
| Subject | Veliparib | Small molecule | 150 mg | Oral |
| Subject | Veliparib | Small molecule | 200 mg | Oral |
| Subject | Veliparib | Small molecule | 250 mg | Oral |
| Subject | Veliparib | Small molecule | 300 mg | Oral |
| Background | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |